Clinical Trial Update: A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing CP-690,550 and etanercept in moderate-to-severe chronic plaque psoriasis; completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• CP-690,550 (tofacitinib)
• Etanercept (etanercept)

Snippet

Sponsor: Pfizer | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2014-05-07